Effective 1 de noviembre de 2019, digestive enzymes added to enteral formula via a cartridge device attached to the tubing used for enteral feeding will be considered not covered for BlueCHiP for Medicare products and not medically necessary for commercial products (e.g., Relizorb™ immobilized lipase cartridge), as the evidence is insufficient to determine the effects of the technology on health outcomes. You can view the full text of this policy here.